The Onset Characteristics and Prognosis of Patients with Radiation-associated Second Primary Malignancy: a Pancancer Study in the US SEER Cancer Registries

Overview

Journal Transl Cancer Res

Specialty Oncology

Date 2024 Nov 11

PMID 39525022

Authors

Yixun Zhang

Ran Wei

Ling Bai

Shuai Jiao

Michael T Milano

Haiyi Liu

Zhigang Wei

Affiliations

Soon will be listed here.

Abstract

Background: Cancer survivors have an elevated risk of developing a second primary malignancy (SPM) after radiation therapy (RT). Data on the association between RT and SPM are limited. Our aim was thus to investigate the impact of RT on the risk of developing SPMs and to evaluate the specific characteristics and prognostic outcomes.

Methods: We enrolled a pancancer cohort using data from the Surveillance, Epidemiology, and End Results registries spanning from January 1973 to December 2015. Multivariable Cox and the Fine-Gray competing risk regression were employed to assess the hazard ratio (HR) and 95% confidence interval (CI) of SPMs in patients who received RT in comparison to those with no RT (NRT). Poisson regression was used to evaluate the RT-associated risks (RR) and the standardized incidence ratio (SIR) for SPMs.

Results: The analysis identified 24 types of risk-increased SPMs (RI-SPMs), including malignancies of the oropharynx, hypopharynx, larynx, esophagus, lung, breast, liver, pancreas, stomach, colon, rectum, ovary, corpus uteri, ureter, vagina, urinary bladder, penis, testis, and kidney, among others. The cumulative incidence of those with RI-SPMs was higher than that of the NRT patients (19.8% 15.3%; P<0.001). The RR for RI-SPMs decreased with increasing age at FPM diagnosis (aged 20-49 years: RR 1.52; age 50-69 years: RR 1.31; age 70 years: RR 1.21), and the RR increased with longer latency period following FPM diagnosis (60-119 months: RR 1.28; 120-239 months: RR 1.24; 240-360 months: RR 1.46). The 10-year overall survival of those with RI-SPMs was significantly lower than that of the matched NRT patients (28.5% 31.7%; P<0.001).

Conclusions: Patients with RI-SPMs warrant greater attention given their time-cumulative onset risk and poor prognosis. Long-term surveillance is necessary for cancer survivors treated with RT.

References

Moschini M, Zaffuto E, Karakiewicz P, D Andrea D, Foerster B, Abufaraj M . External Beam Radiotherapy Increases the Risk of Bladder Cancer When Compared with Radical Prostatectomy in Patients Affected by Prostate Cancer: A Population-based Analysis. Eur Urol. 2018; 75(2):319-328. DOI: 10.1016/j.eururo.2018.09.034. View

Kim M, Lee S, Lee M, Choi J, Han H, Song Y . Risk of Subsequent Primary Cancer in Thyroid Cancer Survivors: A Nationwide Population-Based Study. Diagnostics (Basel). 2023; 13(18). PMC: 10527961. DOI: 10.3390/diagnostics13182903. View

Liu J, Zheng Q, Beeraka N, Zhang X, Li T, Song R . Long-Term Risk of Subsequent Malignant Neoplasms Among Childhood and Adolescent Lymphoma Survivors (1975-2013): A Population-Based Predictive Nomogram. Oncologist. 2023; 28(9):e765-e773. PMC: 10485277. DOI: 10.1093/oncolo/oyad112. View

Guan X, Wei R, Yang R, Lu Z, Liu E, Zhao Z . Association of Radiotherapy for Rectal Cancer and Second Gynecological Malignant Neoplasms. JAMA Netw Open. 2021; 4(1):e2031661. PMC: 7794669. DOI: 10.1001/jamanetworkopen.2020.31661. View

Chaturvedi A, Engels E, Gilbert E, Chen B, Storm H, Lynch C . Second cancers among 104,760 survivors of cervical cancer: evaluation of long-term risk. J Natl Cancer Inst. 2007; 99(21):1634-43. DOI: 10.1093/jnci/djm201. View

Wood M, Vogel V, Ng A, Foxhall L, Goodwin P, Travis L . Second malignant neoplasms: assessment and strategies for risk reduction. J Clin Oncol. 2012; 30(30):3734-45. DOI: 10.1200/JCO.2012.41.8681. View

Geurts Y, Neppelenbroek S, Aleman B, Janus C, Krol A, van Spronsen D . Treatment-specific risk of subsequent malignant neoplasms in five-year survivors of diffuse large B-cell lymphoma. ESMO Open. 2024; 9(2):102248. PMC: 10937196. DOI: 10.1016/j.esmoop.2024.102248. View

Fillon M . Genetic factors contribute to subsequent neoplasms in survivors of childhood cancer. CA Cancer J Clin. 2020; 70(3):143-144. DOI: 10.3322/caac.21603. View

Han C, Wu Y, Kang K, Wang Z, Liu Z, Zhang F . Long-term radiation therapy-related risk of second primary malignancies in patients with lung cancer. J Thorac Dis. 2021; 13(10):5863-5874. PMC: 8575836. DOI: 10.21037/jtd-21-915. View

10.

Casey D, Vogelius I, Brodin N, Roberts K, Avanzo M, Moni J . Risk of Subsequent Neoplasms in Childhood Cancer Survivors After Radiation Therapy: A PENTEC Comprehensive Review. Int J Radiat Oncol Biol Phys. 2023; 119(2):640-654. DOI: 10.1016/j.ijrobp.2023.07.025. View

11.

Yang J, Gao J, Hu J, Hu W, Qiu X, Huang Q . Carbon-ion radiotherapy in the treatment of radiation-induced second primary malignancies. Ann Transl Med. 2022; 10(22):1200. PMC: 9761151. DOI: 10.21037/atm-20-200. View

12.

Preston D, Ron E, Tokuoka S, Funamoto S, Nishi N, Soda M . Solid cancer incidence in atomic bomb survivors: 1958-1998. Radiat Res. 2007; 168(1):1-64. DOI: 10.1667/RR0763.1. View

13.

Smith J, Cust A, Lo S . Risk factors for subsequent primary melanoma in patients with previous melanoma: a systematic review and meta-analysis. Br J Dermatol. 2023; 190(2):174-183. DOI: 10.1093/bjd/ljad275. View

14.

Wallis C, Mahar A, Choo R, Herschorn S, Kodama R, Shah P . Second malignancies after radiotherapy for prostate cancer: systematic review and meta-analysis. BMJ. 2016; 352:i851. PMC: 4775870. DOI: 10.1136/bmj.i851. View

15.

Lee J, Buist D, Houssami N, Dowling E, Halpern E, Gazelle G . Five-year risk of interval-invasive second breast cancer. J Natl Cancer Inst. 2015; 107(7). PMC: 4651041. DOI: 10.1093/jnci/djv109. View

16.

Berrington de Gonzalez A, Curtis R, Kry S, Gilbert E, Lamart S, Berg C . Proportion of second cancers attributable to radiotherapy treatment in adults: a cohort study in the US SEER cancer registries. Lancet Oncol. 2011; 12(4):353-60. PMC: 3086738. DOI: 10.1016/S1470-2045(11)70061-4. View

17.

Stovall M, Weathers R, Kasper C, Smith S, Travis L, Ron E . Dose reconstruction for therapeutic and diagnostic radiation exposures: use in epidemiological studies. Radiat Res. 2006; 166(1 Pt 2):141-57. DOI: 10.1667/RR3525.1. View

18.

Choi Y, Lee M, Kim E, Lee J, Jung I, Cheong J . Risk of Subsequent Primary Cancers Among Adult-Onset 5-Year Cancer Survivors in South Korea: Retrospective Cohort Study. JMIR Public Health Surveill. 2024; 10():e48380. PMC: 11112468. DOI: 10.2196/48380. View

19.

Guan X, Wei R, Yang R, Lu Z, Liu E, Zhao Z . Risk and Prognosis of Secondary Bladder Cancer After Radiation Therapy for Rectal Cancer: A Large Population-Based Cohort Study. Front Oncol. 2021; 10:586401. PMC: 7868538. DOI: 10.3389/fonc.2020.586401. View

20.

Travis L, Demark Wahnefried W, Allan J, Wood M, Ng A . Aetiology, genetics and prevention of secondary neoplasms in adult cancer survivors. Nat Rev Clin Oncol. 2013; 10(5):289-301. DOI: 10.1038/nrclinonc.2013.41. View